The GGA can also be complemented by the company’s second turnkey solution, the Genomatix Mining Station (GMS), which does high-performance NGS mapping. Each GMS node houses 64 gigabytes of memory to be able to handle the terabytes of data, which is necessary to cope with the NGS data output. The GMSs can be scaled-out, just like EMC Isilon units, to match the ever-growing volume of raw data produced by NGS sequencers. The interfaces of both machines are web-based and can be accessed by multiple users without the need to transfer big data.
The company also plans to offer its tools via Illumina’s BaseSpace apps later this year to accommodate users with limited datasets, such as benchtop sequencers.
In collaboration with the NIH, Genomatix software helped to discover synergies between several transcriptional regulatory factors directly influencing maintenance of mammalian photoreceptors. Using chromatin precipitation data and GGA technology, complex regulatory maps of rod and cone genes were assembled. These maps can model the effect of regulatory factors on photoreceptor expression and, thus, better understanding of retinal neurogenerative diseases.
Another key collaboration with the Center for Prostate Disease Research revealed an early biomarker that may predict future metastatic progression of prostate cancer. Genomatix is invested in academic research collaborations, and is an SME partner in various consortiums like BLUEPRINT (generating 100 reference epigenomes), m4 Personalized Medicine (gene network analysis for prognostics and diagnostics on personalized basis), SYNERGY-ERASysBio+ (characterizing roles of nuclear receptors), and MedSyS (signaling in pluripotent stem cells).
“Our approach facilitates translation of genetic data into biomedical knowledge, and we’re working hard to get it into diagnostics,” concluded Dr. Seifert.